Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Non-Current Deffered Revenue: 2020-2022

Historic Non-Current Deffered Revenue for Lyell Immunopharma (LYEL) over the last 2 years, with Sep 2022 value amounting to $37.2 million.

  • Lyell Immunopharma's Non-Current Deffered Revenue fell 54.61% to $37.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $37.2 million, marking a year-over-year decrease of 54.61%. This contributed to the annual value of $79.7 million for FY2021, which is 10.56% down from last year.
  • Latest data reveals that Lyell Immunopharma reported Non-Current Deffered Revenue of $37.2 million as of Q3 2022, which was up 12.86% from $32.9 million recorded in Q2 2022.
  • Lyell Immunopharma's 5-year Non-Current Deffered Revenue high stood at $89.1 million for Q4 2020, and its period low was $32.9 million during Q2 2022.
  • Its 3-year average for Non-Current Deffered Revenue is $68.6 million, with a median of $79.7 million in 2021.
  • Data for Lyell Immunopharma's Non-Current Deffered Revenue shows a maximum YoY plummeted of 59.79% (in 2022) over the last 5 years.
  • Over the past 3 years, Lyell Immunopharma's Non-Current Deffered Revenue (Quarterly) stood at $89.1 million in 2020, then dropped by 10.56% to $79.7 million in 2021, then plummeted by 54.61% to $37.2 million in 2022.
  • Its Non-Current Deffered Revenue was $37.2 million in Q3 2022, compared to $32.9 million in Q2 2022 and $77.9 million in Q1 2022.